Andy Holt

Andy Holt brings more than fifteen years of experience in cell and gene therapy to Ncardia. In his prior roles, he held business development, corporate development, and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing. In his role at Ncardia, Andy leverages his experience in cell and gene therapy platforms to help the company’s clients achieve their drug discovery ambitions.